Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])

NCT02741544 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02741544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02741544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])
Lead sponsor
Celgene
Phase
Observational
Overall status
Completed
Start date
March 3, 2016
Completion date
August 20, 2020
Enrollment
578 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma